Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reissued by analysts at Cowen in a report released on Tuesday.

Other research analysts have also recently issued research reports about the company. Argus reiterated a “buy” rating and issued a $150.00 target price on shares of Incyte in a report on Wednesday, September 13th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Incyte in a report on Wednesday, October 25th. Goldman Sachs Group started coverage on Incyte in a report on Friday, October 6th. They issued a “buy” rating and a $160.00 target price on the stock. Jefferies Group reiterated a “buy” rating on shares of Incyte in a report on Friday, October 6th. Finally, Oppenheimer reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte in a report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $145.65.

Shares of Incyte (INCY) opened at $93.79 on Tuesday. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. Incyte has a 1 year low of $92.91 and a 1 year high of $153.15.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm’s revenue for the quarter was up 41.6% compared to the same quarter last year. research analysts anticipate that Incyte will post -1.33 EPS for the current fiscal year.

In related news, EVP Reid M. Huber sold 696 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bros. Advisors Lp Baker acquired 100,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was purchased at an average cost of $132.00 per share, with a total value of $13,200,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 104,334 shares of company stock worth $11,992,011. Corporate insiders own 17.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in INCY. Wetherby Asset Management Inc. grew its holdings in shares of Incyte by 1.4% during the second quarter. Wetherby Asset Management Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 23 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Incyte by 0.8% during the second quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 67 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Incyte by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 103 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Incyte by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 108 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in shares of Incyte by 2.8% during the second quarter. Teacher Retirement System of Texas now owns 4,855 shares of the biopharmaceutical company’s stock valued at $611,000 after purchasing an additional 133 shares during the last quarter. 90.86% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Incyte (INCY) Stock Rating Reaffirmed by Cowen” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/06/incyte-incy-stock-rating-reaffirmed-by-cowen.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.